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Abstract
Aims: Diabetic cardiomyopathy, characterized by myocardial structural and functional changes, is a specific
cardiomyopathy develops in patients with diabetes mellitus. The present study was to investigate the role of kinin
B2 receptor-Akt-glycogen synthase kinase (GSK)-3b signalling pathway in mediating the protective effects of
tanshinone IIA (TSN) on diabetic cardiomyopathy.
Methods and results: Streptozocin (STZ) induced diabetic rats (n = 60) were randomized to receive TSN, TSN plus
HOE140 (a kinin B2 receptor antagonist), or saline. Healthy Sprague-Dawley (SD) rats (n = 20) were used as control.
Left ventricular function, myocardial apoptosis, myocardial ultrastructure, Akt, GSK-3b and NF-B phosphorylation,
the expression of TNF-a, IL-6 and myeloperoxidase (MPO) were examined. Cardiac function was well preserved as
evidenced by increased left ventricular ejection fraction (LVEF) and ± dp/dt (maximum speed of contraction/
relaxation), along with decreased myocardial apoptotic death after TSN administration. TSN pretreatment alleviated
mitochondria ultrastructure changes. TSN also enhanced Akt and GSK-3b phosphorylation and inhibited NF-B
phosphorylation, resulting in decreased TNF-a, IL-6 and MPO activities. Moreover, pretreatment with HOE140
abolished the beneficial effects of TSN: a decrease in LVEF and ± dp/dt, an inhibition of cardiomyocyte apoptosis, a
destruction of cardiomyocyte mitochondria cristae, a reduction of Akt and GSK-3b phosphorylation, an
enhancement of NF-B phosphorylation and an increase of TNF-a, IL-6 and MPO production.
Conclusion: These data indicated that TSN is cardioprotective in the context of diabetic cardiomyopathy through
kinin B2 receptor-Akt-GSK-3b dependent pathway.
Introduction
Diabetic cardiomyopathy is characterized by cardiac
dysfunction with subsequent heart failure in patients
with diabetes mellitus in the absence of coronary ather-
osclerosis. Over the last decades, there are numerous
studies investigating the underlying pathological
mechanisms of diabetic cardiomyopathy using animal
models of diabetes mellitus as well as clinical data from
diabetic patients. There is evidence that changes in the
extracellular matrix with increased cardiac fibrosis [1-3],
excessive generation of reactive oxygen species [4], as
well as cardiac inflammation [5-7], characterized by
increased levels of pro-inflammatory cytokines may play
a role in the manifestation of diabetic cardiomyopathy.
The kallikrein-kinin system (KKS), which was shown
to exist in the cardiac tissue as a local system [8], might
have beneficial effects in diabetic cardiomyopathy [6].
The effects of kinins are mediated by stimulation of spe-
cific receptors, classified as kinin B1 receptor (B1R) and
kinin B2 receptor (B2R). To date, more knowledge exists
about the function of the B2R, which is thought to med-
iate most of the known cardiovascular beneficial effects
of kinins.
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ponents of tanshinones, exhibits a variety of cardiovascular
activities including vasorelaxation and protection against
ischemia-reperfusion injury and antiarrhythmic effects
[9-11]. The safety of TSN treatment has been well estab-
lished after its widespread application in the treatment of
angina pectoris, acute ischemic stroke and arrhythmia in
Asian countries. However, the effects and mechanisms of
TSN on experimental diabetic cardiomyopathy are not
well understood. Therefore, the aims of the present study
were 1) to determine whether TSN protects against experi-
mental diabetic cardiomyopathy; 2) to identify the role of
B2R in the mechanism responsible for the effects of TSN.
Methods
Animals procedures
HOE140 was used as a kinin B2 receptor antagonist.
Eighty Sprague-Dawley (SD) rats, weight 200 to 220 g,
were randomly allocated into the following groups with
n = 20 each: (1) DM; (2) DM + TSN (TSN); (3) DM +
TSN + HOE140 + I/R (HOE140); (4) control. Diabetes
mellitus (DM) was induced in group (1), (2) and (3) by
intraperitoneal injections of streptozocin (STZ) (50 mg/kg,
STZ was dissolved in 0.1 M citrate buffer, pH 4.5) as pre-
viously described [12].
A one-drop blood sample was obtained at 1, 7 and
12 weeks after STZ injection from all rats through the
tip of the tail for the determination of blood glucose
concentration by using a reflectance meter (Accu-Chek,
Roche Diagnostics GmbH, Mannheim, Germany).
Eleven weeks after STZ was given, TSN (5 mg/kg) was
administered by i.p. injection for seven days. HOE140
(10 μg/kg) was injected via the tail vein 10 min before
TSN injection. Control group received the same volume
of 0.9% saline by i.p. injection for seven days.
One day before, 11 weeks and 12 weeks after STZ was
given, Invasive cardiac hemodynamic analysis was per-
formed similar as previous described [13,14]. In brief,
rats were anesthetized with 3% isoflurane. The left ventri-
cular pressure (LVP) was measured via a Millar Mikro-tip
catheter transducer that was inserted into the left ventri-
cular cavity through the left carotid artery. The left
ventricular systolic pressure (LVSP), left ventricular end-
diastolic pressure (LVEDP), first derivative of the left
ventricular pressure (+dp/dt max and -dp/dt max) and
heart rate were obtained by use of computer algorithms
and an interactive videographics program (Po-Ne-Mah
Physiology Platform P3 Plus, Gould Instrument Systems,
Valley View, Ohio). Of 80 rats, 20 in control group, 17 in
DM group, 17 in TSN group, 18 in HOE140 group sur-
vived the surgery and saline/STZ/TSN/HOE140 adminis-
tration (Figure 1). The experiments were performed in
adherence with the National Institutes of Health Guide-
lines on the Use of Laboratory Animals and were
approved by the Fourth Military Medical University
Committee on Animal Care.
Determination of cardiac function
Cardiac function and dimensions were assessed at 1 day
before, 11 weeks and 12 weeks after STZ was given using
an echocardiography system (Sequoia Acuson, Siemens;
15-MHz linear transducer) under 3% isoflurane inhala-
tion via a nose cone. Cardiac dimensions and function
were assessed by M-mode echocardiography. Left ventri-
cular end-diastolic diameter (LVEDD) and Left ventricu-
lar end-systolic diameter (LVESD) were measured on the
parasternal left ventricular long axis view, All measure-
ments represent the mean of 5 consecutive cardiac cycles.
Left ventricular end-systolic volume (LVESV), Left ven-
tricular end-diastolic volume (LVEDV) and Left ventricu-
lar ejection fraction (LVEF) were calculated by use of
computer algorithms. All of these measurements were
performed in a blinded manner.
Electron microscopy
After echocardiography assessment, rats were anesthe-
tizing with 3% sodium pentobarbital, hearts were rapidly
removed and washed with PBS solution. At a low tem-
perature, a specimen of the left ventricular myocardium
removed with ophthalmic scissors was cut into a 1 mm
tissue mass. Images were taken after fixation, soaking,
stepwise alcohol dehydration, displacement, embedding,
polymerization, sectioning, and staining and observed
with an electron microscope (JEM-2000EX TEM, Japan).
Random sections were taken and analysed by two tech-
nicians blinded to the treatments.
Determination of myocardial apoptosis
Myocardial apoptosis was determined by terminal deox-
yribonucleotidyl transferase-mediated dUTP-biotin nick
end labeling (TUNEL) staining and caspase 3 activity
Figure 1 Study design.
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(AI) = number of TUNEL-positive myocytes/total num-
ber of myocytes stained with DAPI from a total of 40
fields per heart (n = 4). Caspase-3 activity was measured
with the ApoAlert Caspase-3 Assay Plate (Clontech,
Mountain View, Calif) according to the manufacturer’s
instructions. All of these assays were performed in a
blinded manner.
Western blot evaluation and ELISA detection
of cytokine levels
Protein was isolated from homogenized heart tissue with
Trizol reagent (Invitrogen, Carlsbad, Calif) and standard
Invitrogen protocols as previously described [12,13]. The
Bradford assay (Bio-Rad Laboratories, Hercules, Calif)
was used to quantify protein concentrations. Protein was
then used for Western blotting with primary antibodies
against Akt, p-Akt (ser 473), p-GSK-3b (ser 9), GSK-3b,
p-NF-B p65 (ser 536). All of the antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz,
Calif). The blots were visualized with a chemilumines-
cene system (Amersham Bioscience, Buchinghamshire,
UK). The signals were quantified by densitometry. Con-
centrations of TNF-a and IL-6 were measured by com-
mercially available enzyme-linked immunosorbent assay
(ELISA) kits according to the manufacture’s instructions.
Values are expressed as pg/mg of total protein.
Statistical analysis
Continuous variables that approximated the normal dis-
tribution were expressed as means ± SD. Comparison
between groups were subjected to ANOVA followed by
Bonferroni correction for post hoc t test. Data expressed
as proportions were assessed with a Chi-square test or
Fisher’s exact test, as appropriate. Two sided tests have
been used throughout, and P values < 0.05 were consid-
ered statistically significant. SPSS software package ver-
sion 14.0 (SPSS, Chicago, IL) was used for data analysis.
Results
Basic parameters
Heart rate had no statistical differences between groups
both at baseline and at 12 weeks after diabetes was
induced. Blood glucose was significantly elevated in STZ
injection groups (DM, TSN, HOE140) compared with
baseline. Compared with TSN group, diabetic rats in
group DM and group HOE140 had significantly smaller
body weight 12 weeks after diabetes was induced. Heart
to body mass ratio was significantly higher in DM and
HOE140 group compared with TSN group 12 weeks
after STZ injection (Table 1).
TSN preserves left ventricular function in diabetic rats
Hemodynamic measurements were performed at base-
line, 11 w and 12 w after STZ injection (Table 2). In
diabetic hearts, maximum speed of contraction (+ LV
dp/dt max) was significantly decreased as compared
with the control group (3588.1 ± 454.0 vs 4502.4 ±
254.1 mmHg/s, P < 0.05). TSN administration enhanced
+ LV dp/dt max as compared with the diabetes group
(4180.0 ± 747.9 vs 3588.1 ± 454.0 mmHg/s, P < 0.05).
TSN pretreatment also significantly increased the maxi-
mum speed of relaxation (- LV dp/dt max) (3878.4 ±
526.2 vs 3389.9 ± 380.9 mmHg/s, P < 0.05) as compared
with the diabetes group. TSN’se f f e c t so n+L Vd p / d t
max (4180.0 ± 747.9 mmHg/s in TSN group vs 3627.3 ±
199.0 mmHg/s in HOE140 group, P < 0.05) and - LV
dp/dt max (3878.4 ± 526.2 mmHg/s in TSN group vs
3335.7 ± 499.0 mmHg/s in HOE140 group, P <0 . 0 5 )
were abolished by HOE140.
LVEF, ESV, EDV were evaluated by echocardiography
12 w after STZ injection. Table 2 shows that TSN sig-
nificantly improved LVEF in diabetic rats compared
with the diabetes group 12 w after STZ injection, with
LVEF reaching levels similar to those of the control ani-
mals (72.1 ± 5.7 vs 75.5 ± 4.9, P > 0.05). HOE140 abro-
gated the effects of TSN on LVEF enhancement (68.5 ±
5 . 4i nH O E 1 4 0g r o u pvs 67.9 ± 6.0 in diabetes group,
P > 0.05). TSN significantly inhibited the increase of
LVESV compared with the diabetes group (0.31 ± 0.07
vs 0.38 ± 0.08 ml, P <0 . 0 5 )a n dt h eH O E 1 4 0g r o u p
(0.31 ± 0.07 vs 0.37 ± 0.07 ml, P < 0.05). Larger volume
of LVEDV were observed in the diabetes group (1.20 ±
0.08 vs 1.14 ± 0.06 ml, P < 0.05) and the HOE140 group
(1.17 ± 0.08 vs 1.14 ± 0.06 ml, P > 0.05) as compared
with in the TSN group.
Antiapoptotic effect of TSN on cardiomyocytes in rats
with diabetes
Representative results are shown in Figure 2A. STZ-
induced diabetes resulted in markedly increased
TUNEL-positive myocytes compared with the TSN
group (0.132 ± 0.039 vs 0.094 ± 0.028, P < 0.05) (Figure
2B) demonstrated by quantitative analyses. Co-adminis-
tration of HOE140, significantly abolished the antiapop-
totic effect of TSN (0.139 ± 0.030 in HOE140 group vs
0.094 ± 0.028 in TSN group, P < 0.05) (Figure 2B). Con-
currently, levels of caspase-3 activity were determined
and we found that TSN group showed significantly
decreased caspase-3 enzymatic activity compared with
the diabetes group (55.0 ± 20.7 vs 101.7 ± 22.0, P <
0.05) and the HOE140 group (55.0 ± 20.7 vs 98.9 ±
22.3, P < 0.05) (Figure 2C).
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the damage induced by diabetes
Electron microscope showed that the number of cardio-
myocyte mitochondria was increased in the diabetic
group. Cardiomyocyte mitochondria were found greater
in size with the destruction of cristae in experimental
diabetic cardiomyopathy (Figure 3A, B). While TSN
pretreatment alleviated mitochondria ultrastructure
changes with intact membrane and cristae although still
with a greater size which could be reversed by HOE140
(Figure 3C, D).
TSN treatment increases Akt and GSK-3b
phosphorylation, decreases NF-B phosphorylation,
reduces cytokine levels and alleviates leukocyte
infiltration after I/R injury in diabetic rats
To further elucidate the potential mechanism of cardio-
protective effects of TSN. We investigated the effects of
Table 1 Basic parameters of diabetic rats
Basic Parameters Control
(n = 20)
DM
(n = 17)
TSN
(n = 17)
HOE140
(n = 18)
Heart rate (min
-1)
baseline 425.2 ± 12.1 427.6 ± 14.6 420.6 ± 12.1 421.3 ± 15.1
12 w 421.4 ± 29.1 418.1 ± 12.9 415.7 ± 11.6 415.8 ± 14.2
Blood glucose (mmol/L)
baseline 5.1 ± 0.4 5.1 ± 0.5 5.2 ± 0.5 5.1 ± 0.5
12 w 5.1 ± 0.5 25.1 ± 1.1* 24.4 ± 1.1* 25.6 ± 2.7*
Body mass (g)
baseline 197.9 ± 12.5 205.2 ± 12.3 204.1 ± 12.3 206.1 ± 13.2
12 w 531.7 ± 14.9 418.0 ± 14.9* 441.4 ± 20.2*
# 412.8 ± 12.3*
##
Heart to body mass ratio (mg/g)
baseline 1.94 ± 0.19 1.96 ± 0.25 1.90 ± 0.23 1.94 ± 0.26
12 w 1.95 ± 0.21 2.55 ± 0.33* 2.34 ± 0.30*
# 2.46 ± 0.29*
Values are presented as mean ± SD.
*p < 0.05 vs Control,
# p < 0.05 vs DM,
## p < 0.05 vs TSN.
Table 2 Left Ventricular Function Evaluation by Hemodynamic Measurements and Echocardiograpy
Parameters Control
(n = 20)
DM
(n = 17)
TSN
(n = 17)
HOE140
(n = 18)
+LV dp/dt max
baseline 4449.8 ± 190.2 4458.9 ± 318.7 4462.5 ± 253.5 4430.9 ± 455.8
11 w 4528.2 ± 220.4 3678.6 ± 335.2* 3759.8 ± 372.1* 3699.3 ± 257.2*
12 w 4502.4 ± 254.1 3588.1 ± 454.0* 4180.0 ± 747.9
# 3627.3 ± 199.0*
##
-LV dp/dt max
baseline 4359.3 ± 397.9 4464.7 ± 469.9 4215.2 ± 681.4 4127.3 ± 579.7
11 w 4265.1 ± 438.2 3561.5 ± 440.6* 3621.5 ± 582.4* 3655.7 ± 492.8*
12 w 4366.7 ± 418.3 3389.9 ± 380.9* 3878.4 ± 526.2*
# 3335.7 ± 499.0*
##
LVESV (ml)
baseline 0.25 ± 0.06 0.25 ± 0.08 0.25 ± 0.08 0.24 ± 0.08
11 w 0.25 ± 0.05 0.36 ± 0.09* 0.35 ± 0.05* 0.35 ± 0.07*
12 w 0.26 ± 0.06 0.38 ± 0.08* 0.31 ± 0.07*
# 0.37 ± 0.07*
##
LVEDV (ml)
baseline 1.08 ± 0.07 1.08 ± 0.08 1.07 ± 0.07 1.09 ± 0.07
11 w 1.09 ± 0.08 1.21 ± 0.06* 1.20 ± 0.09* 1.19 ± 0.06*
12 w 1.09 ± 0.07 1.20 ± 0.08* 1.14 ± 0.06*
# 1.17 ± 0.08*
LVEF (%)
baseline 76.5 ± 5.8 76.8 ± 7.3 76.0 ± 7.5 78.1 ± 7.1
11 w 75.3 ± 5.2 68.2 ± 7.5* 67.4 ± 7.8* 67.1 ± 6.4*
12 w 75.5 ± 4.9 67.9 ± 6.0* 72.1 ± 5.7
# 68.5 ± 5.4*
##
LVESV, left ventricular end-systolic volume; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; Values are presented as
mean ± SD. *p < 0.05 vs Control,
# p < 0.05 vs DM,
## p < 0.05 vs TSN.
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pathway. TSN treatment was associated with a signifi-
cant increase in phosphorylation of Akt in cardiac tissue
compared with the diabetes group as determined by
western blot analysis. However, with the addition of
HOE140, p-Akt expression was significantly lower than
when the pretreatment was carried out with TSN alone
(Figure 4A). The levels of p-GSK-3b protein were ele-
vated in the TSN group which indicated GSK-3b activa-
tion. The effect of TSN on p-GSK-3b was inhibited by
HOE140 administration (Figure 4B). TSN administration
also associated with reduced expression of phospho-NF-
B p65 protein and this effect was abolished by
HOE140 administration as indicated in Figure 4C.
Figure 2 Antiapoptotic effect of TSN on cardiomyocytes in
diabetic rats. TSN reduced the number of apoptotic
cardiomyocytes compared with the diabetes group and the HOE140
group (A). The number of TUNEL-positive cardiomyocytes (in green,
DAPI in blue) was significantly less in the TSN group than in the
diabetes group and the HOE140 group (B). TSN treatment
significantly decreased caspase-3 activity compared with the
diabetes group and the HOE140 group (C). The columns and errors
bars represent means and SD. *p < 0.05 vs control,
# p < 0.05 vs
diabetes,
## p < 0.05 vs TSN.
Figure 3 TSN protected the cardiomyocytes ultrastructure
against the damage induced by diabetes. Electron micrographs
of control hearts (A) showed regular myofibrillar organization with
evident Z-lines (white arrow) and normal mitochontria profiles
(yellow arrow). In STZ-diabetic hearts (B) and HOE140 pretreatment
hearts (D), great size mitochondria with the destruction of cristae
were detectable. The ultrastructural appearance of the TSN-treated
hearts were similar to controls (C), indicating that the protective
effect on the myocardium preserves the ultrastructure of
cardiomyocytes. Scale bars, 0.5 μm.
Figure 4 Leukocyte infiltration and inflammation cytokines
were alleviated after TSN Administration. A significant increase
in phosphorylation of Akt (Ser 473) (A) and GSK-3b (B) were
observed in myocardial tissue from hearts pretreated with TSN.
Administration of HOE140 shortly before TSN pretreatment
abolished the effects of TSN. The levels of phospho-NF-B p65
protein were elevated in the diabetes group compared with the
control group. TSN administration also associated with reduced
expression of phospho-NF-B p65 protein and this effect was
abolished by HOE140 administration. (C). Consistent with the
changes of NF-B p65 phosphorylation, diabetes resulted in a
noticeable increase in IL-6, TNF-a and MPO compared with control
group. TSN significantly reduced the levels of IL-6, TNF-a and MPO
compared with the diabetes group. However, HOE140
administration significantly increasd IL-6, TNF-a and MPO level
compared with the TSN group (D, E, F). The columns and errors
bars represent means and SD. *p < 0.05 vs control,
# p < 0.05 vs
diabetes,
## p < 0.05 vs TSN.
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tumor necrosis factor-a (TNF-a)( F i g u r e4 D ,E ) .D i a -
betes resulted in a noticeable increase in IL-6 (26.5 ±
6.3 vs 17.1 ± 4.7 pg/mg protein, P < 0.05) and TNF-a
(89.7 ± 10.2 vs 55.9 ± 9.5 pg/mg protein, P < 0.05) com-
pared with the control group. TSN decreased the levels
of IL-6 (20.3 ± 5.5 vs 26.5 ± 6.3 pg/mg protein, P <
0.05) and TNF-a (69.0 ± 12.4 vs 89.7 ± 10.2 pg/mg pro-
tein, P < 0.05) compared with the diabetes group.
HOE140 abolished the effect of TSN, a increased pro-
duction of IL-6 (24.8 ± 5.7 vs 20.3 ± 5.5 pg/mg protein,
P < 0.05) and TNF-a (84.9 ± 9.1 vs 69.0 ± 12.4 pg/mg
protein, P < 0.05) as compared with the TSN group.
The activity of MPO was significantly elevated in the
diabetes group when compared to the control group
(17.6 ± 4.6 vs 6.2 ± 0.6 U/100 mg, P <0 . 0 5 ) .T S Np r e -
treatment reduced MPO activity as compared with the
diabetes group (12.1 ± 4.1 vs 17.6 ± 4.6 U/100 mg, P <
0.05). Co-administration with HOE140 abrogated the
effects of TSN (16.8 ± 4.8 vs 12.1 ± 4.1 U/100 mg, P <
0.05) (Figure 4F).
Discussion
Cardiovascular complications remains the leading cause of
diabetes-related mortality and morbidity [15]. The belief is
widely held that the increase in cardiovascular mortality is
a consequence of accelerated atherosclerosis. However, a
specific disease termed as diabetic cardiomyopathy,
increases the risk for cardiac dysfunction and heart failure
independently of other risk factors such as coronary artery
disease and hypertension as evidenced by compelling epi-
demiological and clinical data [16,17]. Despite the poten-
tial importance of this disease entity, the underlying
mechanisms are still not well understood. Disruption of
the extracellular matrix regulation with accumulation of
cardiac collagen, and furthermore cardiac inflammation
may be an important mediator of this disease.
Salvia miltiorrhiza (Danshen) is an annual sage plant
which grows in China, Mongolia, Korea and Japan. Che-
mical constituents from S. miltiorrhiza root extract are
classified into 2 major categories: water-soluble com-
pounds (WSC) and lipophilic diterpenoid quinines
(LDQ), the compounds of both have been mostly identi-
fied and purified [18]. Among the major diterpenes iso-
lated, including cryptotanshinone, tanshinone I,
tanshinone IIA and dihydrotanshinone, tanshinone IIA
had been shown to posses various pharmacological
activities.
Our previous work has shown that TSN pretreatment
reduces infarct size and improves cardiac dysfunction
after I/R injury in diabetic rats. This was accompanied by
decreased cardiac apoptosis and inflammation. The pos-
sible mechanism responsible for the effects of TSN is
associated with the phosphatidylinositol 3-kinase (PI3K)/
Akt/NF-B-dependent pathway [19]. In addition, TSN
protects against cardiotoxicity induced by doxorubicin in
vitro and in vivo concluded by Jiang and colleagues [20].
Hong [21] et al. reported that tanshinone IIA prevents
doxorubicin induced cardiomyocyte apoptosis through
Akt-dependent pathway. Moreover, TSN also has antic-
ancer properties evidenced by inhibiting the proliferation
of mouse P388 lymphocytic leukemia cells [22], and
inducing apoptosis of human hepatocellular carcinoma
c e l l s[ 2 3 ] ,e t c .A l t h o u g hc a r diomyocyte apoptosis and
inflammatory reaction were increased in experimental
model of diabetic cardiomyopathy and TSN has anti-
apoptosis and anti-inflammation properties. The effects
of TSN on experimental diabetic cardiomyopathy and
the exact mechanism of its therapeutic action are still
poorly understood. This promoted an investigation of the
protective effects of TSN on experimental diabetic cardi-
omyopathy and the underlying mechanism.
In the present study, TSN attenuates cardiac systolic
and diastolic dysfunction in experimental diabetic cardio-
myopathy. TSN treated rats had significantly smaller
LVEDV and LVESV increases and LVEF decrease 12 w
after STZ injection versus diabetic rats. The decrease in
+ LV dp/dt max and - LV dp/dt max also tended to be
smaller in TSN treated rats as compared with diabetic
rats, showing a protective effect of TSN on cardiac func-
tion. Evidence from experimental models and human
cardiac disease shows that cardiomyocytes’ loss as a
result of apoptosis is significant in various heart diseases
and inevitably leads to heart failure [24,25]. Blocking the
apoptosis process could prevent the loss of contractile
cells, minimize cardiac injury and therefore slow down or
even prevent the occurrence of heart failure [26,27].
Thus, we performed TUNEL staining and measured cas-
pase 3 activity in order to explore the underlying
mechanism responsible for the cardiac function improve-
ment induced by TSN in diabetic rats. The results indi-
cated that TSN decreased cardiomyocyte apoptotic index
in diabetic rats which was in agreement with our pre-
vious work which showing potent cardio-protective
effects of TSN. TSN pretreatment alleviated mitochon-
dria ultrastructure changes caused by diabetes as well.
In the present study, diabetic cardiomyopathy is char-
acterized by an decrease in the phosphorylation state of
Akt and GSK-3b, which was associated with augmented
cardiac inflammation as evidenced by increased NF-B
phosphorylation and TNF-a, IL-6 expression, as well as
increased MPO activity. These changes were normalized
by TSN administration. TSN enhanced Akt and GSK-3b
phosphorylation, inhibited NF-Bp h o s p h o r y l a t i o na n d
decreased TNF-a, IL-6 expression and inhibited MPO
activity.
Diabetes mellitus is a growing public health problem
that needs to be tackled at multiple levels such as
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agement of associated comorbidities [16,17,28]. The kal-
likrein-kinin system (KKS), is known to attenuate, e.g.,
cardiac inflammation, fibrosis, apoptosis, and hypertro-
phy when the system is artificially intensified [29]. The
biological effects of kinins in man are mediated by two
G protein coupled receptors, B1and B2. Among these
two receptors, B2 receptor in constitutively expressed
on the surface of many cell types under physiological
conditions [30]. Evidence shows that the B2R is benefi-
cial in myocardial diseases, protecting from inflamma-
tion, fibrosis and apoptosis, while B1R shows a
proinflammatory character contributing to the disease
progression by increasing the production of cytokines
and stimulating the migration of immune cells [31].
HOE140, a specific kinin B2 receptor antagonist, blocks
the vasodilatation and increased vascular permeability
associated with exogenous bradykinin administration
both in experimental models and in vivo in man [32].
In the present study, HOE140 abolished the beneficial
effects of TSN: a decrease in LVEF and ± dp/dt, an inhi-
bition of cardiomyocyte apoptosis, a destruction of car-
diomyocyte mitochondria cristae, a reduction of Akt
and GSK-3b phosphorylation, an enhancement of NF-
B phosphorylation and an increase of TNF-a, IL-6 and
MPO production. Therefore, the kinin B2 receptor
could constitute potential therapeutic targets in the
treatment of diabetic cardiomyopathy. This information
provides important insights regarding the role and
mechanism of TSN in protection against diabetic
cardiomyopathy.
Limitation
The present study only focused on the kinin B2 recep-
tor-Akt-GSK-3b signaling pathway. Some other path-
ways may also participated in the pathogenesis of
diabetic cardiomyopathy such as MAPK related path-
way, etc [33]. Further studies should focus on different
pathways to elucidate more treatment targets of diabetic
cardiomyopathy. Right ventricular function is an impor-
tant factor in evaluating the prognosis of cardiomyopa-
thy [34]. Thus, right ventricular function should be
assessed in the following studies to systematically evalu-
ate the heart function of diabetic cardiomyopathy.
Moreover, the key factors inactivated Akt/GSK-3beta/
NF-B involving increased IL-6, TNF-aand MPO still
need to be clarified in the future studies.
Conclusions
Our findings underscore the cardioprotective effects of
TSN. TSN improves cardiac performance by inhibiting
apoptosis, alleviating mitochondria ultrastructure changes
and reducing inflammatory cytokine production in
experimental diabetic cardiomyopathy. TSN induced car-
dio-protective effects are mediated, at least in part,
through the kinin B2 receptor-Akt-GSK-3b signalling
pathway.
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